Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of drug composition and product containing application

A composition and drug technology, applied in the direction of drug combination, medical preparations containing active ingredients, active ingredients of heterocyclic compounds, etc., can solve problems such as unseen

Active Publication Date: 2013-04-17
SHENZHEN SALUBRIS PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Acute exacerbation of chronic pyelonephritis is one of the urinary system diseases that are difficult to treat at present, and it is mostly treated with integrated traditional Chinese and western medicine. Infection, especially caused by the production of β-lactamase, manifests as moderate or severe acute exacerbation of chronic pyelonephritis, and no effective drugs have been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of drug composition and product containing application
  • Application of drug composition and product containing application
  • Application of drug composition and product containing application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] Screen patients by:

[0099] (1) Inclusion criteria: ①Patients who agreed to participate in this clinical trial and signed the informed consent form; ②Aged 18 to 70 years old, inpatients or outpatients of any gender; ③Clinical diagnosis of complicated urinary tract infection or Patients with acute exacerbation of chronic nephritis nephritis are counted and scored according to their systemic symptoms and local symptoms, and patients with moderate or severe disease severity are screened. The specific evaluation criteria are as follows:

[0100]

[0101]

[0102] Patients who have one of the following conditions will be excluded and will not be included in the experiment:

[0103] 1. Those who have a history of allergies and constitutions to cephalosporins and β-lactam antibiotics.

[0104] 2. Severe infection and other patients who need combined application of antimicrobial drugs.

[0105] 3. Severe heart, liver, and kidney diseases, or ALT, AST, and BUN exceeding...

Embodiment 2

[0116] A composition in which the weight ratio of Compound 1 in terms of free acid and Compound 2 in terms of free acid is 2:1 was given to the 15 patients screened in Example 1 above for a 14-day treatment, wherein the drug Dosage and administration are as follows:

[0117] Moderate infection—the composition of compound 1 and compound 2 for injection (1.5g), dissolved in 10mL of normal saline, then added to 100mL of normal saline for intravenous infusion for 30 minutes, once every 8 hours.

[0118] Severe infection—the composition of compound 1 and compound 2 for injection (2.25g), dissolved in 10mL of normal saline, added to 100mL of normal saline and infused intravenously for 30 minutes, once every 8 hours.

[0119] After the treatment, the treatment effect of the above-mentioned patients was counted: bacteriological effect-clearance rate, clinical effect-effective rate, and comprehensive effect-cure rate. The specific results are as follows:

[0120]

[0121] As can be ...

Embodiment 3

[0126] Screen patients with respiratory infections as follows:

[0127] (1) Inclusion criteria: ①Patients who agreed to participate in this clinical trial and signed the informed consent form; ②Aged 18 to 70 years old, inpatients or outpatients of any gender; ③Patients who were clinically diagnosed with bronchiectasis and infection According to the systemic symptoms and local symptoms they present, the statistics and scoring are carried out, and the patients with moderate or severe disease severity are screened. The specific evaluation criteria are as follows:

[0128]

[0129]

[0130] Patients who have one of the following conditions will be excluded and will not be included in the experiment:

[0131] 1. Those who have a history of allergies and constitutions to cephalosporins and β-lactam antibiotics.

[0132] 2. Severe infection and other patients who need combined application of antimicrobial drugs.

[0133] 3. Severe heart, liver, and kidney diseases, or ALT, AS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a drug composition in preparing a drug for treating infection, in particular to moderate or severe infection, and a product containing the application.

Description

technical field [0001] The invention relates to a composition product and the application of the composition in preparing medicine for treating urinary system infection, especially moderate or severe urinary system infection. Background technique [0002] Compound 1 (structure shown in formula I) is a second-generation semi-synthetic antibiotic used as a broad-spectrum bactericidal antibiotic. [0003] [0004] Compound 2 (structure shown in formula II) is a β-lactamase inhibitor, which can increase the antibacterial activity of antibiotics when used in combination. [0005] [0006] With the widespread clinical application of compound 1, some sensitive strains have developed resistance to compound 1, making its antibacterial effect decline. The results of research and analysis of drug resistance of bacterial strains in many regions of the country show that sensitive bacteria such as Escherichia coli, Proteus mirabilis, and Haemophilus influenzae that are sensitive to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/546A61K31/43A61P31/04A61P13/00
Inventor 孙强张玉生朴永吉
Owner SHENZHEN SALUBRIS PHARMA CO LTD